Unraveling the Nexus: Oncogenic Drivers and Immunotherapy Efficacy in Cancer Treatment

This publication has 29 references indexed in Scilit:

• Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
  Annals of Oncology, 2020
• Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
  Journal of Clinical Oncology, 2020
• Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients
  Cancer Medicine, 2019
• Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
  The Lancet Respiratory Medicine, 2019
• Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
  Clinical Cancer Research, 2019
• Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
  Pharmacological Research, 2018
• Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
  Annals of Oncology, 2018
• EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
  Clinical Cancer Research, 2016
• Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
  Nature Reviews Cancer, 2014
• Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
  Cancer Investigation, 2014